TABLE 1.

Comparative effect of anti-RSV neutralizing monoclonal antibodies on lung RSV-RNA loads, determined by real-time PCR

Mouse group	Acute				Chronic
	Day 1 VL	P	Day 5 VL	P	Day 28 VL	P	Day 70 VL	P
Expt 1
RSV infected, untreated	6.8 ± 0.18		6.5 ± 0.17				156 ± 10.2
Pvz-24 h	6.23 ± 0.34	0.001	6.03 ± 0.44	NSb			226 ± 56.2	NS
MEDI-524 −24 h	5.72 ± 0.28	0.001	5.5 ± 0.29	<0.001			44.7 ± 89.4	NS
Pvz +48 h			6.76 ± 0.39	NS			271 ± 60.4	NS
MEDI-524 +48 h			6.49 ± 0.31	NS			396 ± 185	NS
Expt 2
RSV infected, untreated	8.00 ± 0.77		8.6 ± 0.40		2,825 ± 1,038		54.3 ± 42.2
Pvz-24 h	7.92 ± 0.26	NS	7.42 ± 0.03	0.005	1,429 ± 715	NS	28.1 ± 3.07	NS
MEDI-524 −24 h	7.26 ± 0.19	NS	7.22 ± 0.56	0.005	1,121 ± 684	0.03	5.17 ± 4.58	NS
Pvz +48 h			7.97 ± 0.33	NS	1,192 ± 764	NS	31.1 ± 29.4	NS
MEDI-524 +48 h			7.57 ± 0.17	0.005	787 ± 537	0.03	6.03 ± 6.96	NS

^aData are presented as means ± standard deviations of log₁₀ RNA copies/ml of lung supernatant on days 1 and 5, and as means ± standard deviations of RNA copies/ml on days 28 and 70 from two independent experiments using four mice per time point. Comparisons were made with RSV-infected, untreated controls by one-way analysis of variance.

^bNS, not significant.